 | • レポートコード：MRC2303K050 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の調査レポートでは、世界の移植片対宿主病（GVHD）治療市場規模が、予測期間中（2022年-2027年）、CAGR 8.4％で増大すると予測されています。本レポートでは、移植片対宿主病（GVHD）治療の世界市場を広く調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、疾患別（急性移植片対宿主病、慢性移植片対宿主病）分析、製品別（副腎皮質ホルモン剤、モノクローナル抗体、チロシンキナーゼ阻害剤、その他）分析、エンドユーザー別（病院内薬局、オンライン薬局、小売薬局）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国）分析、競争状況、市場機会・将来動向などについて調査・分析などの項目を掲載しています。並び、こちらのレポートには、Pfizer Inc.、Sanofi (Kadmon Pharmaceuticals)、Astellas Pharma Inc.、Incyte Corporation、AbbVie Inc.、Bristol Myers Squibb Company、Sanofi (Genzyme)、Genentech Inc.などの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の移植片対宿主病（GVHD）治療市場規模：疾患別 - 急性移植片対宿主病における市場規模 - 慢性移植片対宿主病における市場規模 ・世界の移植片対宿主病（GVHD）治療市場規模：製品別 - 副腎皮質ホルモン剤の市場規模 - モノクローナル抗体の市場規模 - チロシンキナーゼ阻害剤の市場規模 - その他移植片対宿主病（GVHD）治療の市場規模 ・世界の移植片対宿主病（GVHD）治療市場規模：エンドユーザー別 - 病院内薬局における市場規模 - オンライン薬局における市場規模 - 小売薬局における市場規模 ・世界の移植片対宿主病（GVHD）治療市場規模：地域別 - 北米の移植片対宿主病（GVHD）治療市場規模 アメリカの移植片対宿主病（GVHD）治療市場規模 カナダの移植片対宿主病（GVHD）治療市場規模 メキシコの移植片対宿主病（GVHD）治療市場規模 … - ヨーロッパの移植片対宿主病（GVHD）治療市場規模 ドイツの移植片対宿主病（GVHD）治療市場規模 イギリスの移植片対宿主病（GVHD）治療市場規模 フランスの移植片対宿主病（GVHD）治療市場規模 … - アジア太平洋の移植片対宿主病（GVHD）治療市場規模 中国の移植片対宿主病（GVHD）治療市場規模 日本の移植片対宿主病（GVHD）治療市場規模 インドの移植片対宿主病（GVHD）治療市場規模 … - 南米/中東の移植片対宿主病（GVHD）治療市場規模 南アフリカの移植片対宿主病（GVHD）治療市場規模 ブラジルの移植片対宿主病（GVHD）治療市場規模 アルゼンチンの移植片対宿主病（GVHD）治療市場規模 … ・競争状況 ・市場機会・将来動向 |
The Graft Versus Host disease treatment market is projected to register a CAGR of 8.4% during the forecast period (2022-2027).
The COVID-19 pandemic has had a significant impact on the market’s growth rate. Graft-versus-Host disease (GvHD) is a condition that occurs in people who have received allogeneic transplantation. The donor immune cells attack the recipient’s body organs and cause a “cytokine storm”. A cytokine storm refers to the overproduction of inflammatory cytokines, which may result in local organ damage. As per a review titled “Systemic and organ-specific immune-related manifestations of COVID-19” published in Nature in 2021, a similar condition occurs during the incidence of COVID-19, where the immune system of the infected individual produces increased levels of inflammatory cytokines, resulting in organ failure. Thus, the severity of the GvHD increases when the patient is affected by COVID-19. The increase in complications posed a serious challenge to the healthcare system globally during the COVID-19 pandemic phase. Thus, there was a surge in demand for Graft-versus-Host disease treatment products to combat the further complications that developed due to COVID-19.
The increasing rate of bone marrow or hematopoietic stem cell treatment, the growing incidence of acute GvHD, and the increasing number of pipeline drugs are likely to propel the market growth throughout the analysis period. For instance, as per a report titled “Graft Versus Host Disease” published by StatPearls Publishing in October 2021, it was found that the incidence of acute GvHD was found to be about 50% for patients receiving HCT from Human Leukocyte Antigen (HLA) matched siblings, and the range was even higher in unmatched donors. The incidence of chronic GvHD was found to be in the range of 6-80%. Additionally, according to an article titled “Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis” published by Elsevier in June 2021, in the United States, 42% of the patients had developed cGvHD within three years of allogenic HCT; 66% of those affected by cGvHD were found to have acute GvHD prior. The refractory nature of cGvHD is expected to propel the growth of the GvHD treatment market.
Furthermore, more research is focused on drugs for GvHD treatment that will have a positive impact on the market’s growth. For instance, a review article titled “New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions” featured in Frontiers in Immunology in October 2020 revealed that a second-line treatment is required for about 50% – 60% of chronic GvHD (cGvHD) patients. Several new strategies are being studied to combat cGvHD by targeting B cells or T cells for immune regulation, thereby reducing inflammation and diminishing the severity of the disease. Additionally, a recent news article by the National Cancer Institute in May 2020 investigated the use of ruxolitinib for treating GvHD patients who do not respond to other treatments based on a randomized clinical trial.
High investments in R&D capabilities by industry players and governments are anticipated to create lucrative opportunities in the market. For instance, in June 2021, Equillium, Inc. reported the completion of an End-of-Phase 1 meeting with the United States Food and Drug Administration (FDA) for itolizumab in the first-line treatment of patients with acute graft-versus-host disease (aGvHD). Thus, the positive outcome of such clinical trials will likely lead to new treatments, which will be expected to boost the market’s growth over the forecast period.
Thus, owing to the abovementioned factors, the market is anticipated to project growth over the forecast period. However, the high cost of GvHD treatment is expected to limit the growth of the market.
Graft Versus Host Disease Treatment Market Trends
The Corticosteroids Segment is Expected to Hold a Major Market Share in the Graft-versus-Host disease treatment Market.
The corticosteroids segment is expected to grow owing to the growing burden of target disease and increasing research studies. The corticosteroids segment is expected to hold the major share in the forecast period due to increasing research and development in corticosteroid and corticosteroid combination therapy to treat HCT patients with Graft-versus-Host disease. Furthermore, according to the article titled “Steroid-refractory chronic graft-versus-host disease: treatment options and patient management” published in July 2021, the absence of second-line treatment for patients suffering from steroid-refractory chronic graft-versus-host disease is concerning. It also demonstrates the huge scope of research that helps benefit the expansion of the Graft-versus-Host disease treatment market.
Additionally, according to the Organ Procurement and Transplantation Network of the United States Department of Human Health Services, around 41,355 transplants were performed in the United States in 2021. Since graft versus host disease is most commonly associated with and might occur after transplants, the demand for corticosteroids as an introductory therapy is likely to increase among the patient population, ultimately driving the segment growth.
Furthermore, research studies carried out to improve the efficiency of the corticosteroids in the treatment are also boosting the growth of the market segment. For instance, as of June 2022, a clinical trial titled “Ruxolitinib-corticosteroid as first-line therapy for newly diagnosed high-risk acute graft versus host disease: study protocol for a multicenter, randomized, phase II-controlled trial” is ongoing. It is an open-label, multicenter, two-arm randomized trial that will evaluate whether the addition of ruxolitinib combined with corticosteroids is superior to corticosteroids alone in newly diagnosed high-risk aGvHD. It was reported that there is about a 50% response rate to first-line therapy with corticosteroids for acute graft versus host disease (aGvHD). The positive outcome of such clinical trials can improve efficiency and thus may lead to segmental growth in the future.
Thus, owing to the abovementioned factors, the market segment is expected to project growth over the forecast period.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
The North American region is expected to hold a significant share in the studied market owing to well-developed healthcare infrastructure, increasing research and development coupled with a growing number of transplants. For instance, according to the data published by the Organ Procurement and Transplantation Network, operated under the United States Department of Health and Human Services, updated in July 2022, the total number of transplants performed in the United States between January 2022 to June 2022 is 20,663. Such an increase in the number of transplant procedures may in turn boost the demand for graft versus host disease treatment owing to the immune-mediated response between donor and recipient adaptive immunity, thus propelling the market’s growth.
Furthermore, the approval from the regulatory authority is also contributing to the growth in the region. For instance, in September 2021, the United States Food and Drug Administration (FDA) approved the use of Ruxolitinib for the treatment of chronic Graft-versus-Host disease after the failure of any two conventional treatments in patients aged 12 years or older. Ruxolitinib is a promising candidate drug since the drug helps to overcome steroid resistance associated with Graft-versus-Host disease.
Additionally, in July 2021, the United States Food and Drug Administration (FDA) approved Belumosudil for the treatment of chronic Graft-versus-Host disease. The drug is permissible for patients older than 12 years and older and those who have already attempted two other treatments. Such approvals are bolstering the growth of the market in the region.
Thus, owing to the abovementioned factors, the North American region is expected to show significant growth over the forecast period.
Graft Versus Host Disease Treatment Market Competitor Analysis
The Graft Versus Host disease treatment market is competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Pfizer Inc., Abbvie Inc., Sanofi (Kadmon Pharmaceuticals), Sanofi (Genzyme), Incyte Corporation, Bristol Myers Squibb Company, Genentech Inc., Astellas Pharma US Inc., and others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Rate of Bone Marrow or Hematopoietic Stem Cell Treatment
4.2.2 Increasing Number of Pipeline Drugs
4.3 Market Restraints
4.3.1 High Cost of Graft-Versus-Host Disease Treatment
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Disease
5.1.1 Acute Graft-Versus-Host disease
5.1.2 Chronic Graft-Versus-Host disease
5.2 By Product
5.2.1 Corticosteroids
5.2.2 Monoclonal antibodies
5.2.3 Tyrosine kinase inhibitors
5.2.4 Others
5.3 By End User
5.3.1 Hospital pharmacies
5.3.2 Online pharmacies
5.3.3 Retail pharmacies
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Rest of the World
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Sanofi (Kadmon Pharmaceuticals)
6.1.3 Astellas Pharma Inc.
6.1.4 Incyte Corporation
6.1.5 AbbVie Inc.
6.1.6 Bristol Myers Squibb Company
6.1.7 Sanofi (Genzyme)
6.1.8 Genentech Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS